BACKGROUND

In this analysis of EUS adult women with HER2-negative ABC, significant differences were observed in demographics and clinical characteristics among BRCA1/2-tested patients compared with BRCA1/2-untested patients.

METHODS

Across all EU5 countries, BRCA1/2 testing rates were generally low, primarily among HR+/HER2-negative patients.

RESULTS

Some percentages add up to greater than 100% due to rounding. Base represents those who are known to be either HR+/HER2-negative or TNBC only.

CONCLUSIONS

In this analysis of EUS adult women with HER2-negative ABC, significant differences were observed in demographics and clinical characteristics among BRCA1/2-tested patients compared with BRCA1/2-untested patients.

Across all EU5 countries, BRCA1/2 testing rates were generally low, primarily among HR+/HER2-negative patients.

Across all EU5 countries, significantly lower BRCA1/2 testing rates were observed among patients with no known family history of BC or OC.

With the broadening of BRCA1/2 testing eligibility criteria and new BRCA1/2 targeted treatment approaches across European BC guidelines, opportunities should be developed to further optimize and increase access to BRCA1/2 testing in Europe.

ACKNOWLEDGEMENTS AND DISCLOSURES

The study was sponsored by Pfizer. External support was provided by Biogen, Inc. and Neutriport’s H110712 and approved by Pfizer. J will declare no conflicts of interest. M.L. disclosed no conflicts of interest. K.L. is a full-time employee of Adelphi Real World. A.N. is a full-time employee of Pfizer. M.P.L. disclosed no conflicts of interest.

REFERENCES

1. European Society for Medical Oncology Congress (ESMO). September 27-October 1, 2019. Berlin, Germany.

